Merck to buy ArQule, advancing leadership in oncology
KENILWORTH, N.J. — Merck and ArQule announced Monday that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire ArQule for $20 per share in cash for an approximate total equity value of $2.7 billion. ArQule is a publicly traded biopharmaceutical company focused on kinase inhibitor discovery and development
